Safety and tolerability of NXY-059 for acute intracerebral hemorrhage: The CHANT trial

Stroke

Volumn 38, Issue 8, 2007, Pages 2262-2269

  Lyden, Patrick D ^a   Shuaib, Ashfaq ^b   Lees, Kennedy R ^c   Davalos, Antoni ^d   Davis, Stephen M ^e   Diener, Hans Christoph ^f   Grotta, James C ^g   Ashwood, Tim J ^h   Hardemark, Hans Goren ^h   Svensson, Hannah H ^h   Rodichok, Larry ⁱ   Wasiewski, Warren W ⁱ   Åhlberg, Gabrielle ^h  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF ALBERTA   (Canada)

^c Gardiner Institute   (United Kingdom)

^d HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^e UNIVERSITY OF MELBOURNE   (Australia)

^f UNIVERSITY OF DUISBURG ESSEN   (Germany)

^g UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

^h ASTRAZENECA R AND D   (Sweden)

ⁱ ASTRAZENECA   (United Kingdom)

Author keywords

Acute care; Clinical trials; Free radical scavengers; Neuroprotectants; Neuroprotection; Neuroprotective agents; Stroke management

Indexed keywords

DISUFENTON SODIUM; PLACEBO; ANTIOXIDANT; BENZENESULFONIC ACID DERIVATIVE; POTASSIUM;

ADULT; AGED; ARTERIOVENOUS MALFORMATION; ARTICLE; ASPIRATION PNEUMONIA; BARTHEL INDEX; BRAIN HEMORRHAGE; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONSCIOUSNESS DISORDER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISABILITY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROPHYSIOLOGY; FEMALE; GLASGOW COMA SCALE; HOSPITAL ADMISSION; HUMAN; IMAGING; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; NEUROLOGIC DISEASE; OUTCOME ASSESSMENT; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RANKIN SCALE; RESPIRATORY DISTRESS; RESPIRATORY FAILURE; RESPIRATORY TRACT INFECTION; RISK FACTOR; SEPSIS; STROKE; TREATMENT OUTCOME; URINARY TRACT INFECTION; ACUTE DISEASE; BLOOD; BRAIN; BRAIN ARTERY; DOWN REGULATION; DRUG ADMINISTRATION; DRUG EFFECT; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; MULTICENTER STUDY; PATHOLOGY; PATHOPHYSIOLOGY; PHYSIOLOGY; TIME; VASCULARIZATION;

ACUTE DISEASE; ADULT; AGED; AGED, 80 AND OVER; ANTIOXIDANTS; BENZENESULFONATES; BRAIN; CEREBRAL ARTERIES; CEREBRAL HEMORRHAGE; DISABILITY EVALUATION; DOUBLE-BLIND METHOD; DOWN-REGULATION; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; INJECTIONS, INTRAVENOUS; MALE; MIDDLE AGED; PLACEBOS; POTASSIUM; TIME FACTORS; TREATMENT OUTCOME;

EID: 34548238171     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.106.472746     Document Type: Article

References (37)

1. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, Gebel J, Mills D, Minneci L, Shukla R. The Greater Cincinnati/Northern Kentucky Stroke Study Preliminary first-ever and total incidence rates of stroke among blacks. Stroke. 1998;29:415.
2. Dennis MS, Burn JPS, Sandercock PAG, Bamford JM, Wade DT, Warlow CP. Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project. Stroke. 1993;24:796.
3. Toni D, Chamorro A, Kaste M, Lees K, Wahlgren NG, Hacke W Acute treatment of ischaemic stroke. European Stroke Initiative. Cerebrovasc Dis. 2004;17 Suppl 2:30-46.
4. Davalos A, Castillo J, Martinez-Vila E. Delay in neurological attention and stroke outcome. Cerebrovascular Diseases Study Group of the Spanish Society of Neurology. Stroke. 1995;26:2233-2237.
5. Leira R, Davalos A, Silva Y, Gil-Peralta A, Tejada J, Garcia M, Castillo J. Early neurologic deterioration in intracerebral hemorrhage: predictors and associated factors. Neurology. 2004;63:461-467.
6. Marler J, Tilley B, Lu M, Brott T, Lyden P, Grotta JC, Broderick J, Levine SR, Frankel M, Horowitz SH, Haley EC, Lewandowski C, Kwiatkowski T, Group Nr-PSS. Early stroke treatment associated with better outcome. Neurology. 2000;55:1649.
7. Hacke W, Donnan G, Fieschi C, Kaste M, von Kummer R, Broderick JP, Brott T, Frankel M, Grotta JC, Haley EC Jr, Kwiatkowski T, Levine SR, Lewandowski C, Lu M, Lyden P, Marler JR, Patel S, Tilley BC, Albers G. Association of outcome with early stroke treatment: pooled analysis of ATLANTIS, ECASS, and NINDS rt-PA stroke trials. Lancet. 2004;363:768.
8. Saver JL, Kidwell C, Eckstein M, Starkman S. Prehospital neuroprotective therapy for acute stroke: results of the Field Administration of Stroke Therapy-Magnesium (FAST-MAG) pilot trial. Stroke. 2004;35:e106.
9. Butcher KS, Baird T, MacGregor L, Desmond P, Tress B, Davis S. Perihematomal edema in primary intracerebral hemorrhage is plasma derived. Stroke. 2004;35:1879-1885.
10. Coyle JT, Puttfarcken P. Oxidative stress, glutamate, and neurodegenerative disorders. Science. 1993;262:689.
11. Fantone JC, Ward PA. Role of oxygen-derived free radicals and metabolites in leukocyte-dependent inflammatory reactions. Am J Pathol. 1982;107:397.
12. Hallenbeck JM, Dutka AJ. Background review and current concepts of reperfusion injury. Arch Neurol. 1990;47:1245.
13. Kuroda S, Tsuchidate R, Smith ML, Maples KR, Siesjo BK. Neuroprotective effects of a novel nitrone, NXY-059, after transient focal cerebral ischemia in the rat. J Cereb Blood Flow Metab. 1999;19:788.
14. Lapchak PA, Araujo DM, Song D, Wei J, Purdy R, Zivin J. Pharmacological effects of the spin trap agent disodium-[(tert-butylimino)methyl]benzene-1,3- disulfonate N-oxide (Pi-by-no NXY-059) on intracerebral hemorrhage in a rabbit large clot thromboembolic stroke model: Combination studies with the thrombolytic tissue plasminogen activator (tPA). Stroke. 2002;33:1665.
15. Maples KR, Ma J, Zhang YK. Comparison of the radical trapping ability of pbn, s-pbn and nxy-059. Free Radic Res. 2001;34:417.
16. Peeling J, Del Bigio MR, Corbett D, Green AR, Jackson DM. Efficacy of disodium 4-[(tert -butylimino)methyl]benzene-1,3-disulfonate N -oxide (NXY-059), a free radical trapping agent, in a rat model of hemorrhagic stroke. Neuropharmacology. 2001;40:433.
17. Sydserff SG, Borelli AR, Green AR, Cross AJ. Effect of NXY-059 on infarct volume after transient or permanent middle cerebral artery occlusion in the rat; studies on dose, plasma concentration and therapeutic time window. Br J Pharmacol. 2002;135:103.
18. Marshall JW, Duffin KJ, Green AR, Ridley RM. NXY-059, a free radical-trapping agent, substantially lessens the functional disability resulting from cerebral ischemia in a primate species. Stroke. 2001;32:190.
19. Marshall JW, Cummings RM, Bowes LJ, Ridley RM, Green AR. Functional and histological evidence for the protective effect of NXY-059 in a primate model of stroke when given 4 hours after occlusion. Stroke. 2003;34:2228.
20. Lees KR, Zivin JA, Ashwood T, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Hardemark HG, Wasiewski WW. NXY-059 for acute ischemic stroke. N Engl J Med. 2006;354:588-600.
21. Lees KR, Davalos A, Davis SM, Diener HC, Grotta J, Lyden P, Shuaib A, Ashwood T, Hardemark HG, Wasiewski W, Emeribe U, Zivin JA. Additional outcomes and subgroup analyses of NXY-059 for acute ischemic stroke in the SAINT I trial. Stroke. 2006;37:2970-2978.
22. Davis SM, Broderick J, Hennerici M, Brun NC, Diringer MN, Mayer SA, Begtrup K, Steiner T. Hematoma growth is a determinant of mortality and poor outcome after intracerebral hemorrhage. Neurology. 2006;66:1175-1181.
23. Hemphill JC 3rd, Bonovich DC, Besmertis L, Manley GT, Johnston SC. The ICH score: a simple, reliable grading scale for intracerebral hemorrhage. Stroke. 2001;32:891-897.
24. Teasdale G, Knill-Jones R, van der Sande J. Observer variability in assessing impaired consciousness and coma. J Neurol Neurosurg Psychiatry. 1978;41:603-610.
25. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31-41.
26. Lyden P, Brott T, Tilley B, Welch KMA, Mascha EJ, Levine S, Haley EC, Grotta J, Marler J, Group NTSS. Improved reliability of the NIH stroke scale using video training. Stroke. 1994;25:2220.
27. Lyden P, Raman R, Liu L, Grotta J, Broderick J, Olson S, Shaw S, Spilker J, Meyer B, Emr M, Warren M, Marler J. NIHSS training and certification using a new digital video disk is reliable. Stroke. 2005;36:2446-2449.
28. Rankin J. Cerebral vascular accidents in patients over the age of 60: Prognosis. Scottish Med J. 1957;2:200.
29. Mahoney FT, Barthel DW. Functional evaluation: Barthel Index. Md State Med J. 1965;14:61.
30. 30a. Duncan PW, Lai SM, Bode RK, Perera S, DeRosa J. Stroke Impact Scale-16: A brief assessment of physical function. Neurology. 2003;60:291-296.
31. 30b. Quinn TJ, Lees KR, Hardemark HG, Dawson J, Walters MR. Initial experience of a digital training resource for modified rankin scale assessment in clinical trials. Stroke. 2007; In press.
32. Broderick JP, Brott TG, Duldner JE, Tomsick T, Huster G. Volume of intracerebral hemorrhage: a powerful and easy-to-use predictor of 30-day mortality. Stroke. 1993;24:987.
33. Candelise L, Pinardi G, Aritzu E, Musicco M. Telephone interview for stroke outcome assessment. Cerebrovascular Diseases. 1994;4:341.
34. Lyden P, Broderick J, Mascha E, Group Nr-PSS, Yamaguchi T, Mori E, Minematsu K, del Zoppo G. Reliability of the Barthel Index Outcome Measure selected for the NINDS t-PA Stroke Trial. Thrombolytic Therapy in Acute Ischemic Stroke III. Tokyo: Springer-Verlag;1995:327.
35. Haley EC Jr, Thompson JL, Levin B, Davis S, Lees KR, Pittman JG, DeRosa JT, Ordronneau P, Brown DL, Sacco RL. Gavestinel does not improve outcome after acute intracerebral hemorrhage: an analysis from the GAIN International and GAIN Americas studies. Stroke. 2005;36:1006-1010.
36. Muir KW, Lees KR, Ford I, Davis S. Magnesium for acute stroke (Intravenous Magnesium Efficacy in Stroke trial): randomised controlled trial. Lancet. 2004;363:439-445.
37. Lyden P, Shuaib A, Ng HK, Atkinson RP, Ashwood T, Nordlund A, Odergren T. The Clomethiazole Acute Stroke Study in Hemorrhagic Stroke (CLASS-H): Final Results. J Stroke Cerebrovasc Dis. 2000;9:268-275.